Northernmost

Executive Summary

Northernmost is a preclinical-stage biotechnology company developing novel therapeutics for neurodegenerative diseases, inspired by Arctic animals' adaptations to extreme environments. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $2.7 million. Its platform leverages unique molecular insights from species such as polar bears and reindeer, which naturally resist neurodegenerative processes despite harsh conditions. This approach targets fundamental mechanisms of protein aggregation and cellular stress, potentially offering first-in-class treatments for conditions like ALS, Alzheimer's, and Parkinson's. Currently in early preclinical development, Northernmost aims to advance lead candidates into in vivo proof-of-concept studies within the next 12-18 months. The limited funding suggests the company may seek strategic partnerships or additional capital to support R&D. While the science is intriguing and differentiated, the preclinical stage carries inherent technical and regulatory risks, making near-term success uncertain. However, the unique approach could attract interest from larger pharma looking for novel neurodegeneration targets.

Upcoming Catalysts (preview)

• Q2 2027Lead optimization and in vivo efficacy data completion40% success
• Q1 2027Series A financing or strategic partnership announcement50% success
• Q3 2027IND-enabling studies initiation30% success